PMID- 16989627
OWN - NLM
STAT- MEDLINE
DCOM- 20061024
LR  - 20071115
IS  - 1744-8395 (Electronic)
IS  - 1476-0584 (Linking)
VI  - 5
IP  - 4
DP  - 2006 Aug
TI  - Can leukemia-derived dendritic cells generate antileukemia immunity?
PG  - 467-72
AB  - Tumor vaccines are being explored as a means of generating antitumor immune 
      responses in patients with cancer. Based on the efficacy of allogeneic 
      transplantation, acute myelogenous leukemia appears to be susceptible to cellular 
      immune-based therapy. Dendritic cells (DCs) are the most potent 
      antigen-presenting cells and, as such, are being studied as a platform for the 
      design of cancer vaccines. In acute leukemia, a promising approach involves the 
      generation of DCs from leukemic blasts via cytokine exposure ex vivo. 
      Leukemia-derived DCs potentially retain the tumor-associated antigens of the 
      leukemic clone, which are presented in the context of the immune stimulating 
      machinery of the mature DC. However, the efficacy of this approach may be limited 
      by intrinsic abnormalities in the malignant clone that prevent differentiation 
      towards a normal DC phenotype.
FAU - Rosenblatt, Jacalyn
AU  - Rosenblatt J
AD  - Beth Israel Deaconess Medical Center, Hematologic Malignancy Bone Marrow 
      Transplant Program, 330 Brookline Avenue, KS 121, Boston, MA 02215, USA. 
      jacalyn_rosenblatt@bidmc.harvard.edu
FAU - Avigan, David
AU  - Avigan D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
SB  - IM
MH  - Dendritic Cells/immunology/*transplantation
MH  - Humans
MH  - Immunotherapy/methods
MH  - Leukemia/*immunology
MH  - Leukemia, Myeloid, Acute/*immunology
MH  - Lymphocyte Depletion
RF  - 57
EDAT- 2006/09/23 09:00
MHDA- 2006/10/25 09:00
CRDT- 2006/09/23 09:00
PHST- 2006/09/23 09:00 [pubmed]
PHST- 2006/10/25 09:00 [medline]
PHST- 2006/09/23 09:00 [entrez]
AID - 10.1586/14760584.5.4.467 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2006 Aug;5(4):467-72. doi: 10.1586/14760584.5.4.467.